Inversago
AcquiredDeveloping next-generation CB1 blockade therapies for metabolic disease.
Montreal, Canada · Founded 2015 · $112.0M raised
- Headquarters
- Montreal
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- inversago.com
- Total Funding
- $112.0M
- Last Round
- $70.0M Series COct 2022
- Rounds
- 3
About
Inversago Pharma specialized in CB1 receptor blockade therapies for metabolic disorders. Acquired by Novo Nordisk in August 2023.
Summary
Inversago is a Biotech company based in Montreal, Canada, founded in 2015. It has raised $112.0M in total across 3 rounds, most recently a $70.0M Series C round in Oct 2022. Investors include Genesys Capital, Amorchem and New Enterprise Associates.
Tech & App Stack
5 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Oct 2022
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...